News & Updates
Filter by Specialty:
Once-weekly icodec affords greater blood sugar reduction than once-daily degludec in T2D
In the treatment of individuals with insulin-naïve type 2 diabetes (T2D), once-weekly icodec yields superior HbA1c reduction compared with once-daily degludec, according to the results of a phase IIIa trial.
Once-weekly icodec affords greater blood sugar reduction than once-daily degludec in T2D
03 Jul 2023
Gas-filled on par with fluid-filled IGB for obesity treatment
Current Food and Drug Administration (FDA)-approved intragastric balloon (IGB) systems, the gas-filled IGB (Obalon) and the fluid-filled IGB (Orbera), demonstrate similar effectiveness for the treatment of obesity, as shown in a recent study.
Gas-filled on par with fluid-filled IGB for obesity treatment
28 Jun 2023
Novel genetic marker predicts CHD risk in Chinese patients with T2DM
Researchers from the Chinese University of Hong Kong (CUHK) have discovered PDE1A rs10171703 as a novel genetic marker for coronary heart disease (CHD) in Chinese patients with type 2 diabetes mellitus (T2DM), indicating its potential utility for predicting CHD risk in this patient population.
Novel genetic marker predicts CHD risk in Chinese patients with T2DM
27 Jun 2023
Debunking the myth: There is no ‘obesity paradox’, new data suggest
Using alternative anthropometric measurements, a post hoc analysis that used data from the PARADIGM-HF* trial debunked the BMI-related ‘obesity paradox’ in a large cohort of patients with chronic heart failure with reduced ejection fraction (HFrEF).